(R)-Baclofen Hydrochloride (STX 209 hydrochloride)
98%
- Product Code: 61672
CAS:
63701-55-3
| Molecular Weight: | 250.12 g./mol | Molecular Formula: | C₁₀H₁₃Cl₂NO₂ |
|---|---|---|---|
| EC Number: | MDL Number: | ||
| Melting Point: | Boiling Point: | ||
| Density: | Storage Condition: | -20°C, airtight, dry |
Product Description:
(R)-Baclofen Hydrochloride, also known as STX 209 hydrochloride, is primarily used in the treatment of spasticity associated with conditions such as multiple sclerosis, spinal cord injuries, and cerebral palsy. It functions as a GABA-B receptor agonist, helping to reduce muscle stiffness and spasms by inhibiting the transmission of signals in the spinal cord. Additionally, it has been explored for its potential in managing alcohol withdrawal symptoms and reducing cravings in individuals with alcohol use disorder. In some cases, it is also being investigated for its effects on improving social behavior and cognitive function in conditions like autism spectrum disorder and Fragile X syndrome. The compound is administered orally or via intrathecal infusion, depending on the severity of the condition and the patient's response to treatment.
Sizes / Availability / Pricing:
| Size (g) | Availability | Price | Quantity |
|---|---|---|---|
| 0.025 | 10-20 days | $2,408.44 |
+
-
|
(R)-Baclofen Hydrochloride (STX 209 hydrochloride)
(R)-Baclofen Hydrochloride, also known as STX 209 hydrochloride, is primarily used in the treatment of spasticity associated with conditions such as multiple sclerosis, spinal cord injuries, and cerebral palsy. It functions as a GABA-B receptor agonist, helping to reduce muscle stiffness and spasms by inhibiting the transmission of signals in the spinal cord. Additionally, it has been explored for its potential in managing alcohol withdrawal symptoms and reducing cravings in individuals with alcohol use disorder. In some cases, it is also being investigated for its effects on improving social behavior and cognitive function in conditions like autism spectrum disorder and Fragile X syndrome. The compound is administered orally or via intrathecal infusion, depending on the severity of the condition and the patient's response to treatment.
| Mechanism | - |
| Appearance | - |
| Longevity | - |
| Strength | - |
| Storage | - |
| Shelf Life | - |
| Allergen(s) | - |
| Dosage (Range) | - |
| Recommended Dosage | - |
| Dosage (Per Day) | - |
| Recommended Dosage (Per Day) | - |
| Mix Method | - |
| Heat Resistance | - |
| Stable in pH range | - |
| Solubility | - |
| Product Types | - |
| INCI | - |
Cart
No products
Subtotal:
$0.00
$0.00
Total :